Table 1. Characteristics of Included Trials.
| Study | Country |
Number (n) |
Mean age (years) |
Gender (n, M/F) |
Type of glioma |
Bevacizumab dose, mg/kg*
(+ other chemotherapy) |
Radiation therapy, total dose (Gy) |
Protocol violations |
Median follow-up | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | C | B | C | B | C | B | C | B | C | B | C | ||||
| Chauffert 2014 | France | 60 | 60 | 60.2 | 60.9 | 34/26 | 37/23 | GBM | 10 (+IRI-125+TMZ-75) | 0 (+IRI-125+TMZ-75) | 60 | 60 | 3/60 | 3/60 | 11.1 month |
| Chinot 2014 | France | 458 | 463 | 57 | 56 | 282/176 | 298/165 | GBM | 10 (+TMZ-75) | 0 (+TMZ-75) | 60 | 60 | 3/458 | 1/463 | 14.4 months (bevacizumab group); 13.7 months (control group) |
| Clarke 2014 | USA | 59 | 133 | 54 | 56 | — | — | GBM | 10 (+ERL-150-200 + TMZ-75) | 0 (+TMZ-75) | 60 | 60 | 0/59 | — | — |
| Vredenburgh 2012 | USA | 125 | 287 | 56.2 | — | 74/51 | — | GBM | 10 (+TMZ-75) | 0 (+TMZ-75) | 59.4 | 60 | 0/32 | — | 21 months |
Abbreviations: B, bevacizumab-treated group; C, control group; GBM, glioblastoma multiforme; IRI-125, inrinotecan at 125 mg/m2 every two weeks for four cycles; TMZ-75, temozolomide at 75 mg/m2 daily; ERL-150-200, erlotinib 150–200 mg daily.
*Standard dosing of bevacizumab given at 10 mg/kg every two weeks.